ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: 84ug MAP0020
Drug: 42ug MAP0020
Drug: 21ug MAP0020

First Posted Date: 2009-10-15

Last Posted Date: 2014-01-09

Lead Sponsor: Allergan

Target Recruit Count: 25

Registration Number: NCT00995904

Locations: 🇺🇸
West Coast Clinical Trials LLC, Cypress, California, United States
🇺🇸
Sylvana Research Associates, San Antonio, Texas, United States

Study of Cyclosporine in Post-LASIK Patients

Phase 2

Completed

Conditions: Laser In Situ Keratomileusis

Interventions: Drug: Cyclosporine 0.005% eye drops
Drug: Cyclosporine 0.010% eye drops
Drug: Placebo (Vehicle for Cyclosporine)

First Posted Date: 2009-10-08

Last Posted Date: 2013-07-11

Lead Sponsor: Allergan

Target Recruit Count: 621

Registration Number: NCT00991458

Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye

Phase 4

Completed

Conditions: Dry Eye Syndromes
Keratoconjunctivitis Sicca

Interventions: Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)
Drug: sodium hyaluronate 0.18% (VISMED® Multi)

First Posted Date: 2009-10-01

Last Posted Date: 2011-09-21

Lead Sponsor: Allergan

Target Recruit Count: 82

Registration Number: NCT00987727

Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Trospium Chloride (Sanctura XR®)
Drug: Metformin hydrochloride (Glucophage®)

First Posted Date: 2009-09-30

Last Posted Date: 2011-12-19

Lead Sponsor: Allergan

Target Recruit Count: 44

Registration Number: NCT00986401

Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation

Not Applicable

Completed

Conditions: Mid-facial Volume Deficit Related to Aging

Interventions: Device: Juvéderm® VOLUMA XC

First Posted Date: 2009-09-16

Last Posted Date: 2015-11-03

Lead Sponsor: Allergan

Target Recruit Count: 345

Registration Number: NCT00978042

Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function

Phase 2

Completed

Conditions: Rhegmatogenous Macula-off Retinal Detachment

Interventions: Drug: 400 ug Brimonidine Implant
Drug: 200 ug Brimonidine Implant
Other: Sham (no implant)

First Posted Date: 2009-09-04

Last Posted Date: 2013-04-24

Lead Sponsor: Allergan

Target Recruit Count: 44

Registration Number: NCT00972374

Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis

Phase 4

Completed

Conditions: Hypotrichosis

Interventions: Drug: bimatoprost ophthalmic 0.03% solution
Drug: vehicle sterile solution (placebo)

First Posted Date: 2009-08-13

Last Posted Date: 2012-01-05

Lead Sponsor: Allergan

Target Recruit Count: 89

Registration Number: NCT00958035

Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms

Phase 4

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: carboxymethylcellulose 0.5% +glycerin 0.9%
Drug: sodium hyaluronate 0.18%

First Posted Date: 2009-07-14

Last Posted Date: 2011-10-31

Lead Sponsor: Allergan

Target Recruit Count: 71

Registration Number: NCT00938704

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

Not Applicable

Completed

Conditions: Dry Eye Syndrome

Interventions: Drug: Glycerin and Polysorbate 80 based artificial tear

First Posted Date: 2009-07-03

Last Posted Date: 2015-08-26

Lead Sponsor: Allergan

Target Recruit Count: 47

Registration Number: NCT00932477

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

Phase 4

Completed

Conditions: Obesity
Overactive Bladder
Incontinence

Interventions: Drug: Trospium Chloride, Extended Release (XR)
Other: placebo

First Posted Date: 2009-07-02

Last Posted Date: 2013-01-21

Lead Sponsor: Allergan

Target Recruit Count: 127

Registration Number: NCT00932022

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy